Last reviewed · How we verify

Control Analgesic regimen

Ain Shams University · FDA-approved active Small molecule

A control analgesic regimen combines multiple pain-relief agents to manage pain through complementary mechanisms.

A control analgesic regimen combines multiple pain-relief agents to manage pain through complementary mechanisms. Used for Acute and chronic pain management.

At a glance

Generic nameControl Analgesic regimen
Also known asEpidural Bupivacaine
SponsorAin Shams University
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Control analgesic regimens typically employ a multimodal approach, combining agents such as opioids, non-steroidal anti-inflammatory drugs (NSAIDs), and/or adjuvant analgesics to target pain through different pathways—reducing inflammation, blocking pain signal transmission, and modulating pain perception. This combination approach aims to improve efficacy while potentially reducing the dose-dependent adverse effects of any single agent.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: